Postes, I have no doubt generics can get the supply to meet their needs If they chose to. This is more about how much will they need and when will they need it. To answer your question about what will AMRN will do with all the extra IPE if generics win, there won’t be any extra. Amarin will sell it as GV in the US and the rest will go to EU and ROW. I also believe AMRN GV ( if needed) will be priced competitively or lower than competitors. I sure hope we get a reversal and all this will be moot. This case seems ripe for reversal.
News 
Market Data 
Discover 
AI
